Stay updated on IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib
Sign up to get notified when there's something new on the IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib page.

Latest updates to the IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib page
- Check4 days agoChange DetectedTaiwan site entry updated in the locations list: Taoyuan, Taiwan, 333 was removed and Taoyuan County, Taiwan, 333 was added. This reflects a site name adjustment in the same region.SummaryDifference0.0%

- Check11 days agoChange DetectedA new revision entry, v3.5.3, was added to the page, replacing the previous v3.5.2. This reflects an updated version or patch release being recorded as the current revision.SummaryDifference0.0%

- Check19 days agoChange DetectedThe page’s displayed revision/version has been updated from **v3.5.0** to **v3.5.2**.SummaryDifference0.0%

- Check33 days agoChange DetectedLocation entry updated to Padova, Veneto, Italy (35128), replacing Padua for the site.SummaryDifference0.0%

- Check48 days agoChange DetectedThe page's revision label was updated from v3.4.3 to v3.5.0. No substantive study content changes are indicated.SummaryDifference0.0%

- Check55 days agoChange DetectedAdded Hepatocellular carcinoma as a topic. Included a Resources section with a link to the Genetic and Rare Diseases Information Center.SummaryDifference0.1%

Stay in the know with updates to IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib
Enter your email address, and we'll notify you when there's something new on the IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib page.